MedTrace Logo

Convalescent Plasma Therapy for Hospitalized Patients With COVID-19

NCT05077930 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2023-11-29

No results posted yet for this study

Summary

Plasma from donors who have recovered from coronavirus disease 2019 (COVID-19) contain antibodies to SARS-CoV-2 and may be a potential therapy for hospitalized patients with COVID-19. The efficacy of high-titer convalescent plasma for COVID-19, however, still unclear. The present study aims to evaluate the efficacy and safety of using convalescent plasma for treating hospitalized patients with COVID-19.

Conditions

Interventions

BIOLOGICAL

Convalescent plasma

The intervention group will receive 200 or 400 mL of high-titer COVID-19 convalescent plasma, ABO compatible with the patient, within 24 hours of randomization.

DRUG

Standard of care

The active comparator group will receive oxygen supplementation, corticoids, antiretrovirals, and/or monoclonal antibodies according to the institutional protocol.

Sponsors & Collaborators

  • Centro de Hematologia e Hemoterapia do Paraná - Hemepar

    collaborator UNKNOWN

  • Fundação Oswaldo Cruz, Instituto Carlos Chagas, ICC Paraná

    collaborator UNKNOWN

  • Science Valley Research Institute

    collaborator OTHER

  • Tânia Portella Costa

    lead OTHER

Principal Investigators

  • Kengi Itinose, MD · Maternidade e Cirurgia Nossa Senhora do Rocio/ SA - Hospital do Rocio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-06
Primary Completion
2022-04-04
Completion
2022-04-07

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05077930 on ClinicalTrials.gov